MediWound , an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous leg ulcers.

Jerusalem: MediWound, an Israeli developer of products to treat burns and wounds using non-surgical tissue repair, said on Wednesday it was starting a Phase III trial for its treatment for venous ...

The nature of ulcer pain often changes as the condition progresses. What begins as a mild burning sensation can evolve into more intense and frequent discomfort. Gastroenterologists note that ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

What is a pressure ulcer or bedsore? A pressure ulcer, or bedsore, is an area of skin - and sometimes also the tissue underneath - that has become damaged because of pressure. An ulcer may develop ...

Gastrointestinal (GI) symptoms are the hallmark of Crohn’s disease, but this autoimmune condition can affect any part of the digestive system, including the mouth. Oral symptoms might even be ...

Peptic ulcer disease is a common digestive disorder in which acid and digestive enzymes cause the lining of the stomach or the first part of the small intestine (duodenum) to erode. A peptic ulcer ...

EscharEx is currently being investigated in a global Phase III study for the treatment of venous leg ulcers (VLUs). Preparations are underway for a Phase II/III study targeting diabetic foot ulcers ...

DALLAS, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Spectral AI (NASDAQ: MDAI) (“Spectral AI” or the “Company”), developer of the AI-driven DeepView ® System, which received Breakthrough Device Designation from ...

Objective An international meeting was organised to develop consensus on (1) the landmarks to define the gastro-oesophageal junction (GOJ), (2) the occurrence and pathophysiological significance of ...

Recently, the stable gastric pentadecapeptide BPC 157 was shown to counteract major vessel occlusion syndromes, i.e., peripheral and/or central occlusion, while activating particular collateral ...